iShares MSCI Indonesia ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.65, while Recursion Pharmaceuticals Inc trades at $3.27 (market cap $1.81B). The key difference: iShares MSCI Indonesia ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EIDO | RXRX | |
|---|---|---|
52-Week High | $19.22 | $6.79 |
52-Week Low | $10.80 | $2.84 |
Market Cap | — | $1.81B |
Sector | — | Health |
Enterprise Value | — | $1.33B |
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $12.64, down 0.86% on the day, with a bearish technical signal from moving averages and mixed oscillators. The stock faces headwinds from foreign capital outflows in Asian equities and Indonesia's economic exposure. A dividend of $0.23 is scheduled for payment in June 2026, offering income potential amid weak price action.
The outlook remains cautious due to technical downtrends and macroeconomic pressures on Indonesian assets. Investment appeal hinges on valuation discounts and potential policy support, but risks include currency volatility and limited earnings growth. Investors require patience for a turnaround.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Trailing returns across standard periods
Latest headlines on both assets
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →